CD8A and neoplasm: STING agonists (MSA-2, ADU-S100) were used in vitro (qRT-PCR for CXCL10, CCL5 induction) and in vivo (intracardiac inoculation of cancer cells in mice, followed by agonist treatment). Disseminated tumor burden, immune cell depletion (NK, CD4+, CD8+), and survival analyses assessed STING-dependent dormancy maintenance.